Moderna
Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.
Top Stages
7 past transactions
immatics biotechnologies
Post in 2023
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.
The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.
immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.
Generation Bio
Post in 2023
Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.
Metagenomi
Series B in 2023
Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.
OriCiro Genomics
Acquisition in 2023
OriCiro Genomics is a Japanese biotechnology company founded in 2018, based in Minato-ku. It specializes in developing innovative genome technologies, particularly focusing on cell-free synthesis and amplification of large DNA molecules for synthetic biology applications. The company's core technologies include DNA assembly and circular DNA amplification, which enable the construction of large circular DNA molecules without traditional biological cloning methods. OriCiro Genomics serves life science research and development companies, offering solutions that facilitate advancements in gene therapy, pharmaceuticals, diagnostics, food, and agriculture by leveraging synthetic biology.
Metagenomi
Series B in 2022
Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.
Leightal Capital Management
Debt Financing in 2022
Leightal Capital Management is a global hedge fund that invests in a variety of asset classes, including equities, fixed income, and commodities. The fund is managed by a team of experienced professionals with a proven track record of success.
Leightal Capital Management is committed to providing its investors with superior returns over the long term. The fund's investment philosophy is based on the belief that alpha can be generated by identifying and investing in mispriced assets.
The fund's investment team uses a variety of research and analysis techniques to identify mispriced assets. The team also has a strong focus on risk management and capital preservation.
Leightal Capital Management is a good choice for investors who are looking for a long-term investment partner with a proven track record of success.
Onkaido Therapeutics
Venture Round in 2014
Onkaido Therapeutics is focused on developing messenger RNA therapeutics aimed at delivering innovative oncology drugs. The company is advancing pre-clinical drug candidates that target key biological processes such as apoptosis, central regulatory nodes, and immunotherapy. This approach enables healthcare professionals to address a range of oncology-related and infectious diseases that existing treatments may not effectively manage. Through its research and development efforts, Onkaido aims to enhance treatment options for patients facing these challenging medical conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.